OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results

World J Urol. 2015 Dec;33(12):2095-101. doi: 10.1007/s00345-015-1578-4. Epub 2015 May 13.

Abstract

Purpose: To investigate the effects of onabotulinum toxin type A (Onabot/A) intravesical injections on urinary and sexual function in a group of patients affected by multiple sclerosis (MS).

Methods: We enrolled 31 MS female patients with symptoms of overactive bladder and detrusor overactivity. All patients underwent urodynamics and were administered 3-day voiding diary, Incontinence Quality of Life (I-QoL) questionnaire, Female Sexual Function Index (FSFI) questionnaire, Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D) before and 3 months after Onabot/A intravesical injection.

Results: Onabot/A injection significantly improved urinary symptoms as shown by the 3-day voiding diary, I-QoL questionnaire and the urodynamic variables. In addition, it also significantly improved sexual functioning in continent patients and psychological status as demonstrated by the increase in FSFI, HAM-A and HAM-D scores.

Conclusions: The Onabot/A-induced positive effect on sexual dysfunction in our MS patients is likely due to an indirect effect exerted by the overall urological clinical improvement on sexual function at both the psychological and emotional levels. The positive effect exerted by Onabot/A on the anxiety and depression scale also suggests that urinary symptoms have a negative impact on the psychological status of the patients.

Keywords: Intradetrusorial injections; Multiple sclerosis; OnabotulinumtoxinA; Sexual dysfunction.

Publication types

  • Clinical Trial

MeSH terms

  • Acetylcholine Release Inhibitors / therapeutic use*
  • Administration, Intravesical
  • Adult
  • Anxiety
  • Botulinum Toxins, Type A / therapeutic use*
  • Depression
  • Female
  • Humans
  • Middle Aged
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / psychology*
  • Quality of Life
  • Sexuality*
  • Surveys and Questionnaires
  • Urination Disorders / etiology
  • Urination Disorders / prevention & control

Substances

  • Acetylcholine Release Inhibitors
  • Botulinum Toxins, Type A